Search results
Showing 406 to 420 of 456 results for learning disabilities
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)
This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....
View recommendations for HTE17Show all sections
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Virtual ward platform technologies for acute respiratory infections (HTE13)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....
View recommendations for HTE13Show all sections
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.